[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-1-en-105":3,"doc-seo-563730-105":53,"doc-detail-563730-en":126},{"code":4,"msg":5,"data":6},0,"success",[7,14,19,24,29,34,39,44,49],{"id":8,"doc_module":9,"doc_module_name":10,"category_name":11,"show_sort_weight":12,"slug":13},11,1,"Template","Presentations",90,"presentations",{"id":15,"doc_module":9,"doc_module_name":10,"category_name":16,"show_sort_weight":17,"slug":18},12,"Resumes",80,"resumes",{"id":20,"doc_module":9,"doc_module_name":10,"category_name":21,"show_sort_weight":22,"slug":23},14,"Invoices",70,"invoices",{"id":25,"doc_module":9,"doc_module_name":10,"category_name":26,"show_sort_weight":27,"slug":28},15,"Posters",60,"posters",{"id":30,"doc_module":9,"doc_module_name":10,"category_name":31,"show_sort_weight":32,"slug":33},16,"Social Media",50,"social-media",{"id":35,"doc_module":9,"doc_module_name":10,"category_name":36,"show_sort_weight":37,"slug":38},17,"Forms",40,"forms",{"id":40,"doc_module":9,"doc_module_name":10,"category_name":41,"show_sort_weight":42,"slug":43},18,"Letters",30,"letters",{"id":45,"doc_module":9,"doc_module_name":10,"category_name":46,"show_sort_weight":47,"slug":48},21,"Paper Templates",5,"papers-templates",{"id":50,"doc_module":9,"doc_module_name":10,"category_name":51,"show_sort_weight":4,"slug":52},158,"General","general-158",{"code":4,"msg":54,"data":55},"ok",{"site_id":56,"language":57,"slug":58,"title":59,"keywords":60,"description":61,"schema_data":62,"social_meta":119,"head_meta":121,"extra_data":123,"updated_unix":125},105,"en","systemic-menopause-hormone-therapy-mht-equivalency-table-general-guidance-and-intended-use-dose-equivalencies","Systemic Menopause Hormone Therapy (MHT) Equivalency Table - General Guidance and Intended Use - Dose Equivalencies","","Systemic Menopause Hormone Therapy (MHT) Equivalency Table provides approximate dose comparisons to help healthcare providers initiate or switch between common estrogen and progestogen formulations used in menopause management. It is intended as a general clinical guide and does not replace individualized clinical judgment. Equivalencies are based on expert consensus, ranges are used when evidence is limited, and the table emphasizes patient-specific variation and product-specific non-interchangeability.",{"@graph":63,"@context":118},[64,80,101],{"@type":65,"itemListElement":66},"BreadcrumbList",[67,71,74,77],{"item":68,"name":69,"@type":70,"position":9},"https://docshare.wps.com","Home","ListItem",{"item":72,"name":10,"@type":70,"position":73},"https://docshare.wps.com/template/",2,{"item":75,"name":36,"@type":70,"position":76},"https://docshare.wps.com/template/forms/",3,{"item":78,"name":59,"@type":70,"position":79},"https://docshare.wps.com/template/systemic-menopause-hormone-therapy-mht-equivalency-table-general-guidance-and-intended-use-dose-equivalencies/563730/",4,{"url":78,"name":59,"@type":81,"image":82,"author":87,"headline":59,"publisher":90,"fileFormat":93,"inLanguage":57,"description":61,"dateModified":94,"datePublished":95,"encodingFormat":93,"isAccessibleForFree":96,"interactionStatistic":97},"DigitalDocument",{"url":83,"@type":84,"width":85,"height":86},"https://docshare.wps.com/thumbnails/systemic-menopause-hormone-therapy-mht-equivalency-table-general-guidance-and-intended-use-dose-equivalencies/563730.png","ImageObject",442,249,{"name":88,"@type":89},"xXChrisXx","Person",{"url":68,"name":91,"@type":92},"DocShare","Organization","application/pdf","2026-10-16","2026-10-12",true,{"@type":98,"interactionType":99,"userInteractionCount":9},"InteractionCounter",{"@type":100},"ViewAction",{"@type":102,"mainEntity":103},"FAQPage",[104,110,114],{"name":105,"@type":106,"acceptedAnswer":107},"What is the purpose of this MHT equivalency table?","Question",{"text":108,"@type":109},"It helps healthcare providers initiate or switch between various estrogen and progestogen formulations used in menopause management. It serves as a general clinical guide and does not replace individualized clinical judgment.","Answer",{"name":111,"@type":106,"acceptedAnswer":112},"Are the dose equivalencies exact across different products?",{"text":113,"@type":109},"No. The table provides approximate equivalencies based on expert consensus, and absorption varies between products and individuals. Evidence limitations and clinical variability are reflected using ranges where needed.",{"name":115,"@type":106,"acceptedAnswer":116},"How should progestogen dosing be selected for endometrial protection?",{"text":117,"@type":109},"Recommended progestogen doses are based on consensus and international guidelines for endometrial protection. Higher-dose estrogen, unscheduled bleeding, and cyclical needs may require different progestogen dosing strategies.","https://schema.org",{"og:url":78,"og:type":120,"og:title":59,"og:site_name":91,"og:description":61},"article",{"robots":122,"canonical":78},"index,follow",{"doc_id":124,"site_id":56},563730,1792112565,{"code":4,"msg":5,"data":127},{"doc_id":124,"user_id":128,"nickname":88,"user_avatar":129,"doc_module":9,"category_id":35,"category_name":36,"doc_title":59,"doc_description":61,"doc_content":130,"file_id":131,"file_url":132,"file_type":133,"file_size":134,"view_count":9,"is_deleted":4,"is_public":9,"is_downloadable":9,"audit_status":9,"page_count":73,"language":135,"language_code":57,"site_id":56,"html_lang":57,"table_of_contents":136,"faqs":137,"seo_title":138,"seo_description":61,"update_tm":139,"read_time":9},8796112263567,"https://ap-avatar.wpscdn.com/davatar_3d24733baf745e90a7e4bdd5f77d97b2","Systemic Menopause Hormone Therapy ( MHT) Equivalency Table  \nGeneral Guidance and Intended Use: This equivalency table is intended as a general clinical guide to assist healthcare providers in initiating or switching between various estrogen and progestogen formulations commonly used in menopause management. It is not intended to replace individualized clinical judgment or account for all patient-specific factors.  \nBasis of Equivalency The dose equivalencies provided are approximate and based on expert consensus from members of the Canadian Menopause Society (CMS) , drawing on international guidelines including the British Menopause Society (BMS) and International Menopause Society (IMS) . Where evidence is limited or conflicting, ranges are presented to reflect variability in clinical practice and interpretation of available data. Dose comparisons are rough equivalencies, as absorption varies both between products anbetween individuals.  \n\n| Trade Name (Active Ingredient) | Ultra Low | Low | Standard Dose | Moderate-High | High\u003Cbr>(POI/Early\u003Cbr>Menopause) |\n| --- | --- | --- | --- | --- | --- |\n| ORAL Estrogen |  |  |  |  |  |\n| Estrace (estradiol), tablet | - | 0.5 mg | 1 mg | 2 mg | 3-4 mg |\n| Premarin (conjugated estrogen), tablet | - | 0.3 mg | 0.625 mg | - | 1.25 mg |\n| TRANSDERMAL Estrogen |  |  |  |  |  |\n| Estrogel (0.06% estradiol), gel 1 pump = 0.75 mg |  | 1 pump | 1-2 pumps | 2-3 pumps | 4 pumps |\n| Divigel (0. 1% estradiol), gel | 0.25 mg sachet | 0.5 mg sachet | 1.0 mg sachet | 1.0 mg + 0.5 mg\u003Cbr>sachet | 1.0 mg sachet x 2 |\n| Estradot (estradiol), patch\u003Cbr>Change twice a week | - | 25-37.5 mcg | 50 mcg | 75 mcg | 100 mcg |\n| Climara (estradiol), patch\u003Cbr>Change once a week | - | 25 mcg | 50 mcg | 75 mcg | 100 mcg |\n| COMBINATION THERAPIES (Estrogen with the Recommended Dose of Progestogen for Endometrial Protection) |  |  |  |  |  |\n| Bijuva (1 mg estradiol with\u003Cbr>100 mg micronized progesterone), capsule | - | - | 1 capsule | - | - |\n| Activelle LD (0.5 mg estradiol with 0.1 mg norethindrone), tablet | - | m1 tablet | - | - | - |\n| Activelle (1 mg estradiol with 0.5 mg norethindrone), tablet | - | - | 1 tablet | - | - |\n| Angeliq (1 mg estradiol with 1 mg drospirenone), tablet | - | - | 1 tablet | - | - |\n| Estalis (50 mcg estradiol/ 250 mcg norethindrone), patch\u003Cbr>Change twice a week | - | - | 1 patch | - | - |\n| Estalis (50 mcg estradiol /140 mcg norethindrone), patch\u003Cbr>Change twice a week | - | - | 1 patch | - | - |\n\n| Progestogen Doses Recommended for Endometrial Protection |  |  |  |  |  |\n| --- | --- | --- | --- | --- | --- |\n| Prometrium (Micronized Progesterone), capsule\u003Cbr>Continuous (daily) | 100 mg | 100 mg | 100 mg-200 mg | 200 mg | ≥ 200 mg |\n| Prometrium (Micronized Progesterone), capsule\u003Cbr>Cyclical (sequential) | 200 mg\u003Cbr>x 12-14 days\u003Cbr>each month | 200 mg\u003Cbr>x 12-14 days\u003Cbr>each month | 200 mg\u003Cbr>x 12-14 days\u003Cbr>each month | ≥ 200 mg\u003Cbr>x 12-14 days\u003Cbr>each month | ≥ 200 mg\u003Cbr>x 12-14 days\u003Cbr>each month |\n| Provera (Medroxy Progesterone Acetate), tablet Continuous (daily) | 2.5 mg | 2.5 mg | 2.5-5 mg | 5 mg | 5 mg |\n| Provera (Medroxy Progesterone Acetate), tablet\u003Cbr>Cyclical (sequential) | 5 mg\u003Cbr>x 10-12 days\u003Cbr>each month | 5 mg\u003Cbr>x 10-12 days\u003Cbr>each month | 10 mg\u003Cbr>x 10-12 days\u003Cbr>each month | 10 mg\u003Cbr>x 10-12 days\u003Cbr>each month | 10 mg\u003Cbr>x 10-12 days\u003Cbr>each month |\n| Norlutate (norethindrone acetate), tablet |  |  | 5 mg |  |  |\n| Mirena IUS (levonogestrel 52 mg/IUS, up to 5 years) | Yes | Yes | Yes | Yes | Yes |\n| MHT Products Which Do Not Require A Progestogen (Estrogenic effects but formulation also protects endometrial lining) |  |  |  |  |  |\n| Duavive (0.45 mg conjugated estrogen with 20 mg bazedoxifene), tablet |  |  | 1 tablet |  |  |\n| Tibella (2.5 mg tibolone), tablet |  |  | 1 tablet |  |  |\n\nFootnotes & Guidance Notes  \n* Serum Estradiol Levels These equivalencies are not based on serum estradiol or pharmacokinetic data. No robust head-to-head studies of serum level","cbCaia34zEQfnnR3","https://ap.wps.com/l/cbCaia34zEQfnnR3","pdf",359431,"English","# General Guidance and Intended Use\n## Basis of Equivalency\n## Dose Equivalencies by Formulation\n## Progestogen Doses for Endometrial Protection\n## MHT Products Without Required Progestogen\n## Footnotes & Guidance Notes","[{\"question\":\"What is the purpose of this MHT equivalency table?\",\"answer\":\"It helps healthcare providers initiate or switch between various estrogen and progestogen formulations used in menopause management. It serves as a general clinical guide and does not replace individualized clinical judgment.\"},{\"question\":\"Are the dose equivalencies exact across different products?\",\"answer\":\"No. The table provides approximate equivalencies based on expert consensus, and absorption varies between products and individuals. Evidence limitations and clinical variability are reflected using ranges where needed.\"},{\"question\":\"How should progestogen dosing be selected for endometrial protection?\",\"answer\":\"Recommended progestogen doses are based on consensus and international guidelines for endometrial protection. Higher-dose estrogen, unscheduled bleeding, and cyclical needs may require different progestogen dosing strategies.\"}]","Systemic Menopause Hormone Therapy (MHT) Equivalency Table - General Guidance and Intended Use - Dose Equivalencies | PDF",1791837944]